Asia Pacific Warts Therapeutics Market

Market Introduction

Warts are skin growth caused by the human papillomavirus (HPV). There are more than 60 types of HPV, some of which tend to cause warts on the skin. Topical treatments could probably resolve the issue of warts in a few weeks with minimal side effects. Topical treatment of may not be effective all the time. Hence, cryotherapy with liquid nitrogen is a suitable option for treatment, where cure rate is 60% to 90% with less than 20% to 10% recurrence rate.

Thus, the new product developments are expected to create a significant demand for warts therapeutics in the coming years, which is further anticipated to drive the warts therapeutics market.

The COVID-19 pandemic has brought unprecedented challenges globally. It has put a major strain on the health systems of many countries around the world and disrupted many services including HPV screening. The COVID-19 pandemic threatens to reverse progress in reducing the burden of HPV in the region. The impact of COVID-19 on North-East Asia is tremendous due to the concentration of economic activities and demographics. While the pandemic has impeded the progress in many of the Sustainable Development Goals (SDGs) and even reversed some of the achievements. Most countries in the subregion have relatively low levels of GDP, further hampering the advancements of the many healthcare policies. In addition, resources are redirected to COVID-19, many state and local public health programs have been unable to sustain pre–COVID-19 levels of activity in the prevention and control of other communicable diseases. Such negative impacts have already been reported regarding HIV, viral hepatitis, STIs, and tuberculosis programs. The decrease in staffing coupled with reduced diagnostic capability resulting in shortages of STD screening and limited ability to perform in-person patient care because of social distancing requirements have negatively impacted the market growth.

Market Overview and Dynamics

The Warts therapeutics market in Asia Pacific is expected to grow from US$ 415.0 million in 2021 to US$ 541.5 million by 2028; it is estimated to grow at a CAGR of 3.9% from 2021 to 2028. Warts are caused by various strains of human papillomaviruses (HPV), and different strains cause warts in different parts of the body. Healthy persons coming in contact with warts can acquire the infection. Moreover, the recurrence rate for genital warts is high. As per the National Center for Biotechnology Information (NCBI), ~30% of total warts cases are expected to regress within the first four months of infection. HPV infections lead to cervical cancer, and cervical cancer is the fourth most common cancer among women. As per the World Health Organization (WHO), ~570,000 new cases of cervical cancer recorded in 2018 with high prevalence in low-income countries. Hence, an increase in the prevalence of HPV infections, leading to a rise in wart cases, and the high recurrence rate of warts are driving the wart therapeutics market growth.

Key Market Segments

In terms of type, the common warts segment accounted for the largest share of the Asia Pacific warts therapeutics market in 2020. In terms of treatment, the physical destruction segment accounted for the largest share of the Asia Pacific warts therapeutics market in 2020. In terms of end user, the hospitals segment accounted for the largest share of the Asia Pacific warts therapeutics market in 2020.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the warts therapeutics market in Asia Pacific are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Bausch Health Companies Inc., Euro Vital Pharma GmbH, Cipla Inc., Koninklijke Utermöhlen NV, Scholl's Wellness Company, Teva Pharmaceutical Industries Ltd, GlaxoSmithKline plc., and Novan, Inc.

Reasons to buy report

• To understand the Asia Pacific Warts therapeutics market landscape and identify market segments that are most likely to guarantee a strong return
• Stay ahead of the race by comprehending the ever-changing competitive landscape for Asia Pacific Warts therapeutics market
• Efficiently plan M&A and partnership deals in Asia Pacific Warts therapeutics market by identifying market segments with the most promising probable sales
• Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Asia Pacific Warts therapeutics market
• Obtain market revenue forecast for market by various segments from 2021-2028 in Asia Pacific region.

ASIA PACIFIC WARTS THERAPEUTICS MARKET SEGMENTATION

By Type

• Common Warts
• Genital Warts
• Flat Warts
• Others

By Treatment

• Physical Destruction

• Cryotherapy
• Surgical Removal
• Laser Treatment

• Immunomodulation

• Interferons
• Retinoids
• Zinc

• Chemical Destruction

• Bleomycin
• Cantharidin
• Salicylic Acid
• Others

By End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

By Country

• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific

Companies Mentioned

1. Bausch Health Companies Inc.           
2. Euro Vital Pharma GmbH                 
3. Cipla Inc.                 
4. Koninklijke Utermöhlen NV                 
5. Scholl's Wellness Company             
6. Teva Pharmaceutical Industries Ltd                  
7. GlaxoSmithKline plc.          
8. Novan, Inc

Asia Pacific Warts Therapeutics Market Strategic Insights

Asia Pacific Warts Therapeutics Market Segmentation Analysis

Asia Pacific Warts Therapeutics Market Report Highlights

Asia Pacific Warts Therapeutics Report Scope

Asia Pacific Warts Therapeutics Market Country and Regional Insights